The global market for Hepatitis C Treatment was estimated at US$121.8 Billion in 2024 and is projected to reach US$224.6 Billion by 2030, growing at a CAGR of 10.7% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Hepatitis C Treatment market.
Global Hepatitis C Treatment Market - Key Trends & Drivers Summarized
What Are the Latest Breakthroughs in Hepatitis C Treatment?
Hepatitis C, a viral infection that primarily affects the liver, has witnessed transformative advancements in its treatment landscape. Historically, treatment regimens included lengthy interferon-based therapies that often came with severe side effects and variable success rates. However, the advent of direct-acting antivirals (DAAs) has revolutionized hepatitis C treatment. These DAAs, such as Sofosbuvir, Ledipasvir, and Daclatasvir, target specific steps in the hepatitis C virus lifecycle, leading to cure rates exceeding 95% with shorter treatment durations and fewer side effects. The simplification of treatment regimens and the introduction of pangenotypic DAAs have further expanded treatment accessibility, making it feasible to treat a broader range of patients effectively.
How Are New Therapies Improving Patient Outcomes?
The implementation of new therapies has significantly improved patient outcomes in hepatitis C management. DAAs offer a much shorter treatment duration, often just 8 to 12 weeks, compared to the previous interferon-based treatments that could last up to a year. This reduction in treatment time, combined with the minimal side effects of DAAs, has greatly enhanced patient adherence and overall experience. Moreover, these therapies have proven effective across all stages of liver disease, from early-stage fibrosis to advanced cirrhosis. The high efficacy rates of DAAs have also contributed to a marked decrease in hepatitis C-related complications, such as liver cancer and liver failure, thereby improving long-term health outcomes for patients.
Why Is Global Access to Hepatitis C Treatment Expanding?
Global access to hepatitis C treatment has expanded significantly due to a combination of policy initiatives, generic drug production, and international collaborations. Many countries have implemented national hepatitis C elimination programs, aiming to diagnose and treat all infected individuals. The production of generic versions of DAAs has drastically reduced the cost of treatment, making it affordable for low- and middle-income countries. Additionally, collaborations between pharmaceutical companies, governments, and non-governmental organizations have facilitated large-scale treatment programs and awareness campaigns. These efforts are supported by the World Health Organization`s goal to eliminate hepatitis C as a public health threat by 2030, driving widespread testing and treatment initiatives globally.
What Are the Key Drivers of Market Growth?
The growth in the hepatitis C treatment market is driven by several factors. Technological advancements in drug formulation and delivery have enhanced treatment efficacy and patient compliance. The increasing prevalence of hepatitis C, particularly among high-risk populations, has escalated the demand for effective treatments. Enhanced diagnostic techniques and widespread screening programs enable early detection and prompt intervention, broadening the treatment landscape. Regulatory approvals of new and improved DAAs, coupled with robust investment in research and development by pharmaceutical companies, fuel market expansion. Public health initiatives and international efforts to eliminate hepatitis C also significantly contribute to market growth. Additionally, partnerships between stakeholders, including governments, healthcare providers, and pharmaceutical companies, foster innovation and accelerate the availability of advanced treatment options. These factors collectively drive the dynamic and rapidly evolving hepatitis C treatment market.
SCOPE OF STUDY:
The report analyzes the Hepatitis C Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments: Drug Class (HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy, Interferon & Antiviral)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
Market Growth: Understand the significant growth trajectory of the HCV Protease Inhibitors segment, which is expected to reach US$25.3 Billion by 2030 with a CAGR of a 9.2%. The HCV Polymerase Inhibitors segment is also set to grow at 10.3% CAGR over the analysis period.
Regional Analysis: Gain insights into the U.S. market, valued at $32.6 Billion in 2024, and China, forecasted to grow at an impressive 14.7% CAGR to reach $49.6 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
Detailed Market Analysis: Access a thorough analysis of the Global Hepatitis C Treatment Market, covering all major geographic regions and market segments.
Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Hepatitis C Treatment Market.
Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
How is the Global Hepatitis C Treatment Market expected to evolve by 2030?
What are the main drivers and restraints affecting the market?
Which market segments will grow the most over the forecast period?
How will market shares for different regions and segments change by 2030?
Who are the leading players in the market, and what are their prospects?
Report Features:
Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
Company Profiles: Coverage of players such as AbbVie, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC and more.
Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 123 companies featured in this Hepatitis C Treatment market report include:
AbbVie, Inc.
Bristol-Myers Squibb Company
F. Hoffmann-La Roche AG
Gilead Sciences, Inc.
GlaxoSmithKline PLC
Johnson & Johnson
Kadmon Holdings, Inc.
Merck & Co., Inc.
This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:
Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Tariff Impact on Global Supply Chain Patterns
Global Economic Update
Hepatitis C Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Introduction of Direct-Acting Antivirals (DAAs)
High Cure Rates with Shorter Treatment Durations
Increasing Screening and Diagnosis Rates
Rising Awareness and Government Initiatives
Development of Pangenotypic Regimens
Growing Focus on HCV Elimination Programs
Advancements in Liver Disease Management
Increasing Investment in R&D Activities
Expanding Access to Healthcare in Developing Regions
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Hepatitis C Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Hepatitis C Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Hepatitis C Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 4: World 15-Year Perspective for Hepatitis C Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for HCV Protease Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for HCV Protease Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 7: World 15-Year Perspective for HCV Protease Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for HCV Polymerase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for HCV Polymerase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 10: World 15-Year Perspective for HCV Polymerase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for HCV NS5A Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for HCV NS5A Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 13: World 15-Year Perspective for HCV NS5A Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Combination Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Combination Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 16: World 15-Year Perspective for Combination Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Interferon & Antiviral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Interferon & Antiviral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 19: World 15-Year Perspective for Interferon & Antiviral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 20: USA Recent Past, Current & Future Analysis for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 21: USA Historic Review for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 22: USA 15-Year Perspective for Hepatitis C Treatment by Drug Class - Percentage Breakdown of Value Sales for HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral for the Years 2015, 2025 & 2030
CANADA
TABLE 23: Canada Recent Past, Current & Future Analysis for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 24: Canada Historic Review for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 25: Canada 15-Year Perspective for Hepatitis C Treatment by Drug Class - Percentage Breakdown of Value Sales for HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral for the Years 2015, 2025 & 2030
JAPAN
Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 26: Japan Recent Past, Current & Future Analysis for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 27: Japan Historic Review for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 28: Japan 15-Year Perspective for Hepatitis C Treatment by Drug Class - Percentage Breakdown of Value Sales for HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral for the Years 2015, 2025 & 2030
CHINA
Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 29: China Recent Past, Current & Future Analysis for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 30: China Historic Review for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 31: China 15-Year Perspective for Hepatitis C Treatment by Drug Class - Percentage Breakdown of Value Sales for HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral for the Years 2015, 2025 & 2030
EUROPE
Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 32: Europe Recent Past, Current & Future Analysis for Hepatitis C Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 33: Europe Historic Review for Hepatitis C Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 34: Europe 15-Year Perspective for Hepatitis C Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
TABLE 35: Europe Recent Past, Current & Future Analysis for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 36: Europe Historic Review for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 37: Europe 15-Year Perspective for Hepatitis C Treatment by Drug Class - Percentage Breakdown of Value Sales for HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral for the Years 2015, 2025 & 2030
FRANCE
Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 38: France Recent Past, Current & Future Analysis for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 39: France Historic Review for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 40: France 15-Year Perspective for Hepatitis C Treatment by Drug Class - Percentage Breakdown of Value Sales for HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral for the Years 2015, 2025 & 2030
GERMANY
Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 41: Germany Recent Past, Current & Future Analysis for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 42: Germany Historic Review for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 43: Germany 15-Year Perspective for Hepatitis C Treatment by Drug Class - Percentage Breakdown of Value Sales for HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral for the Years 2015, 2025 & 2030
ITALY
TABLE 44: Italy Recent Past, Current & Future Analysis for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 45: Italy Historic Review for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 46: Italy 15-Year Perspective for Hepatitis C Treatment by Drug Class - Percentage Breakdown of Value Sales for HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral for the Years 2015, 2025 & 2030
UNITED KINGDOM
Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 47: UK Recent Past, Current & Future Analysis for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 48: UK Historic Review for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 49: UK 15-Year Perspective for Hepatitis C Treatment by Drug Class - Percentage Breakdown of Value Sales for HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral for the Years 2015, 2025 & 2030
SPAIN
TABLE 50: Spain Recent Past, Current & Future Analysis for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 51: Spain Historic Review for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 52: Spain 15-Year Perspective for Hepatitis C Treatment by Drug Class - Percentage Breakdown of Value Sales for HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral for the Years 2015, 2025 & 2030
RUSSIA
TABLE 53: Russia Recent Past, Current & Future Analysis for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 54: Russia Historic Review for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 55: Russia 15-Year Perspective for Hepatitis C Treatment by Drug Class - Percentage Breakdown of Value Sales for HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 57: Rest of Europe Historic Review for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 58: Rest of Europe 15-Year Perspective for Hepatitis C Treatment by Drug Class - Percentage Breakdown of Value Sales for HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral for the Years 2015, 2025 & 2030
ASIA-PACIFIC
Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis C Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 60: Asia-Pacific Historic Review for Hepatitis C Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 61: Asia-Pacific 15-Year Perspective for Hepatitis C Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 63: Asia-Pacific Historic Review for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 64: Asia-Pacific 15-Year Perspective for Hepatitis C Treatment by Drug Class - Percentage Breakdown of Value Sales for HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral for the Years 2015, 2025 & 2030
AUSTRALIA
Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
INDIA
Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
SOUTH KOREA
REST OF ASIA-PACIFIC
LATIN AMERICA
Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
ARGENTINA
BRAZIL
MEXICO
REST OF LATIN AMERICA
MIDDLE EAST
Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
IRAN
ISRAEL
SAUDI ARABIA
UNITED ARAB EMIRATES
REST OF MIDDLE EAST
AFRICA
Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
IV. COMPETITION
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
The Hepatitis C Drug market is a subset of the larger Infectious Diseases Drugs market. It is composed of drugs used to treat the Hepatitis C virus, a contagious virus that can cause liver damage. These drugs are typically administered orally or intravenously and can be used to treat both acute and chronic infections. The drugs are designed to reduce the amount of virus in the body, reduce the risk of liver damage, and improve the quality of life for those infected.
The Hepatitis C Drug market is highly competitive, with many companies offering treatments. Some of the major players in the market include Gilead Sciences, AbbVie, Merck, Bristol-Myers Squibb, and Janssen Pharmaceuticals. Other companies, such as Mylan, Cipla, and Natco Pharma, also offer treatments for the virus. Show Less Read more
This product is a market research report. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a market research report. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a market research report. This is a 1-10 user license, allowing up to ten users have access to the product. The product is a PDF. This product is a market research report. This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF.
The sample excerpt is provided to help you make an informed purchasing decision. It is not intended to serve as free content or replace a full report. To ensure the sample aligns with your specific needs, our team will contact you to better understand your requirements.
An error occurred while sending the message. Should this issue persist, email us at help@researchandmarkets.net
*Required Information
This website uses cookies to ensure you get the best experience. Learn more